MTACU — MedTech Acquisition Income Statement
0.000.00%
- $93.11m
- $92.97m
Annual income statement for MedTech Acquisition, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | 10-K/A | 10-K | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||
| Total Operating Expenses | 0.108 | 3.04 | 2.75 |
| Operating Profit | -0.108 | -3.04 | -2.75 |
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -0.711 | 4.77 | 6.11 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -0.711 | 4.77 | 5.54 |
| Net Income Before Extraordinary Items | |||
| Net Income | -0.711 | 4.77 | 5.54 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -0.711 | 4.77 | 5.54 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -0.023 | 0.153 | 0.187 |